Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
批准号:
10685264
负责人:
E. John Wherry
金额:
$54.08万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-22 至 2025-08-31
关键词:
AddressAffectAntigensBindingBinding SitesBiologicalBiologyCD8-Positive T-LymphocytesCRISPR screenCRISPR/Cas technologyCellsChromatinChronicClinicalClustered Regularly Interspaced Short Palindromic RepeatsComplementComplexDNA BindingDataDefectDependenceDevelopmental BiologyEnzymesEpigenetic ProcessExcisionExonsFoundationsFunctional disorderGenesGenetic TranscriptionGenomeGenomicsGoalsHIVHepatitis B VirusHepatitis C virusHeterogeneityHistonesImmune responseImmunityImmunologicsInfectionLoxP-flanked alleleLymphocytic choriomeningitis virusMaintenanceMalignant NeoplasmsMediatingModelingMolecularMorbidity - disease rateMusPD-1 blockadePD-1 pathwayPathway interactionsPatientsPersonsPlayPopulationPropertyReporterRepressionRoleSignal TransductionT-LymphocyteT-bet proteinTestingTherapeuticTherapeutic InterventionTranscriptional RegulationTransferaseVirus DiseasesWorkchromatin remodelingchronic infectionclinical effectdisorder controlexhaustexhaustionflexibilitygain of functionimprintimprovedin vivoinducible Creinsightloss of functionmortalitynovelnovel therapeuticsnuclear factors of activated T-cellspreventprogenitorprogrammed cell death protein 1programsrecruitresponsetherapeutic targettranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
T cell exhaustion is common during chronic infections and cancer and limits control of disease. Targeting TEX by
blocking pathways such as PD-1:PD-L can reinvigorate these cells leading to dramatic clinical effects in cancer.
However, most patients do not receive durable clinical benefit. Although PD-1 pathway blockade re-invigorates
TEX function, and results in transcriptional changes, there is little change in the chromatin landscape and
functional changes are not sustained. Thus, our ability to target TEX for therapeutic benefit in cancer and chronic
infections is limited by the epigenetic inflexibility of these cells. A better understanding of the initiation, stability
and reversibility of TEX epigenetic identity should reveal new therapeutic possibilities.
We and others have recently identified Tox as the epigenetic lineage programmer of TEX. Without Tox, TEX cannot
form. Tox is required to initiate chromatin remodeling for TEX but represses terminal TEFF differentiation. However,
the mechanisms of how Tox programs epigenetics are unclear. A major question is what happens to chromatin
landscape and TEX differentiation if Tox is removed in established TEX. Addressing this question is a major goal.
TEX heterogeneity is also now pointing to a developmental biology hierarchy with discreet, functionally relevant
stages of differentiation – or TEX subsets - controlled by transcription factor circuits. These subsets also differ
epigenetically suggesting key roles for Tox that are as yet untested as well as opportunities.
These observations suggest a key role for Tox in the epigenetic identity of TEX but raise key questions about the
ongoing role of Tox once TEX are established. Our overall hypothesis is that inducible deletion of Tox in
established TEX will reveal mechanisms of epigenetic stability of TEX and opportunities for therapeutic
improvement during chronic infections and cancer. We will test this hypothesis in the following Aims:
AIM 1: TEST WHETHER DELETION OF TOX IN ESTABLISHED TEX ALTERS TEX DIFFERENTIATION, TRANSCRIPTIONAL
PROGRAM, OPEN CHROMATIN LANDSCAPE AND/OR DYNAMICS OF TEX SUBSETS. We hypothesize that removal of Tox
in established TEX will revert the TEX epigenetic program and will be associated with functional, differentiation
and transcriptional changes that will be augmented by PD-1 blockade and/or removal of antigen. To test this
idea we will use new inducible Tox deletion strategies combined with deep mechanistic interrogation of the
cellular developmental biology, transcriptional and epigenetic program and response to PD-1 pathway blockade.
AIM 2: TEST HOW COMPLEMENTARY OR DOWNSTREAM EPIGENETIC OR TRANSCRIPTIONAL CIRCUITS COOPERATE WITH
TOX IN TEX. We hypothesize that a combination of in vivo CRISPR screening and candidate testing will reveal
epigenetic and transcriptional mechanisms of Tox in TEX. We will use this CRISPR approach together with
enforced expression strategies and a novel Tox-driven inducible Cre reporter to define the molecular and
genomic mechanisms of Tox-mediated initiation and maintenance of the TEX lineage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering HIV-specific T cells that have improved function and persistence
-
批准号:9891735
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2020
-
负责人:E. John Wherry
-
依托单位:
Engineering HIV-specific T cells that have improved function and persistence
-
批准号:10617349
-
项目类别:
-
资助金额:$40.08万
-
财政年份:2020
-
负责人:E. John Wherry
-
依托单位:
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
-
批准号:10096485
-
项目类别:
-
资助金额:$53.94万
-
财政年份:2020
-
负责人:E. John Wherry
-
依托单位:
Engineering HIV-specific T cells that have improved function and persistence
-
批准号:10450648
-
项目类别:
-
资助金额:$40.16万
-
财政年份:2020
-
负责人:E. John Wherry
-
依托单位:
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
-
批准号:10267763
-
项目类别:
-
资助金额:$54.08万
-
财政年份:2020
-
负责人:E. John Wherry
-
依托单位:
Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox
-
批准号:10462695
-
项目类别:
-
资助金额:$54.08万
-
财政年份:2020
-
负责人:E. John Wherry
-
依托单位:
Engineering HIV-specific T cells that have improved function and persistence
-
批准号:10165494
-
项目类别:
-
资助金额:$40.43万
-
财政年份:2020
-
负责人:E. John Wherry
-
依托单位:
Project 3: Genetic and epigenetic basis of resistance to RT and ICB
-
批准号:10360425
-
项目类别:
-
资助金额:$53.42万
-
财政年份:2017
-
负责人:E. John Wherry
-
依托单位:
Project 3: Genetic and epigenetic basis of resistance to RT and ICB
-
批准号:10005192
-
项目类别:
-
资助金额:$53.42万
-
财政年份:2017
-
负责人:E. John Wherry
-
依托单位:
Core C - Functional Genomics and Computational Biology Core
-
批准号:10670293
-
项目类别:
-
资助金额:$21.07万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Project 3 - Modulation of Antiviral Immunity and T cell Exhaustion by Inhibitory Receptors
-
批准号:10023670
-
项目类别:
-
资助金额:$44.67万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Functional Genomics Core
-
批准号:8854449
-
项目类别:
-
资助金额:$23.24万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Project 3 - Modulation of Antiviral Immunity and T cell Exhaustion by Inhibitory Receptors
-
批准号:10670297
-
项目类别:
-
资助金额:$43.25万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Core C - Functional Genomics and Computational Biology Core
-
批准号:10023666
-
项目类别:
-
资助金额:$22.49万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Project 3 - Modulation of Antiviral Immunity and T cell Exhaustion by Inhibitory Receptors
-
批准号:10239113
-
项目类别:
-
资助金额:$43.25万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Project 3 - Modulation of Antiviral Immunity and T cell Exhaustion by Inhibitory Receptors
-
批准号:10663578
-
项目类别:
-
资助金额:$43.25万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Core C - Functional Genomics and Computational Biology Core
-
批准号:10663574
-
项目类别:
-
资助金额:$21.07万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Core C - Functional Genomics and Computational Biology Core
-
批准号:10239108
-
项目类别:
-
资助金额:$21.07万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Defining the role of microRNAs in CD8 T cell exhaustion
-
批准号:9012770
-
项目类别:
-
资助金额:$24.0万
-
财政年份:2015
-
负责人:E. John Wherry
-
依托单位:
Cellular and transcriptional control of exhausted CD8 T cells lineage dynamics
-
批准号:8636658
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2014
-
负责人:E. John Wherry
-
依托单位:
海外基金